Wells Fargo Maintains Overweight on Eli Lilly, Raises Price Target to $825
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal has maintained an Overweight rating on Eli Lilly (LLY) and increased the price target from $700 to $825.
February 06, 2024 | 9:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo analyst Mohit Bansal has reaffirmed an Overweight rating on Eli Lilly and raised the price target from $700 to $825.
The increase in price target by a reputable analyst suggests a strong confidence in Eli Lilly's future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100